Corpus Uteri, Phase II
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alison Johnson
- Anca Bulgaru, MD
- Andrea Brennan
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Blair Colette McNamara, MD
- Catherine Wei, MD
- Clarice Grens
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Elena Ratner, MD, MBA
- Emily Collier, MD
- Francesca Montanari, MD
- Gary Altwerger, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jamie Malette
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Jose Morales-Marin
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Katyayani (Katya) Papatla, MD/MPH
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Larisa Fleysher
- Madeline Santiago
- Martha Diaz
- Masoud Azodi, MD
- Matthew Austin, MD
- Megin Iaccarino
- Michael Cohenuram, MD
- Michael Grant, MD
- Michelle Greenman
- Mitchell Clark, MD, MPH
- Natalia Buza, MD
- Neal Fischbach, MD
- Nesrine Khoury
- Pawan Karanam, MD
- Peter Dottino, MD, FACOG
- Rebecca Bartomeli
- Renee Moye
- Robert Legare, MD
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Thomen, APRN
- Stacey LaRosa
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated11/14/2024
- Study HIC#2000026850